Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Society for Maternal-Fetal Medicine Statement: Response to the Food and Drug Administration’s withdrawal of 17-alpha hydroxyprogesterone caproate

American Journal of Obstetrics and Gynecology(2023)10.1016/j.ajog.2023.04.012Source: DataRank Database

Society for Maternal-Fetal Medicine Statement: Response to the Food and Drug Administration’s withdrawal of 17-alpha hydroxyprogesterone caproate is a research paper published in American Journal of Obstetrics and Gynecology (2023). On theSindex it has a DataRank of 0.681. It has been cited 20 times, with 20 citing works in its 1-hop citation network.

N/A

0.681DataRank · unranked

Scored on demand from live citation data

20 citations · 20 citing works in its network

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)OA: bronzeTopics (16)IDs (PubMed)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 67%Citation Network 33%

Base Score Contribution

0.457

From this paper's citation signal

Citation Network Contribution

0.225

From 10 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 20 citers.

Vaginal progesterone for the prevention of recurrent spontaneous preterm birth
American Journal of Obstetrics & Gynecology MFM202314 citations47 referencesContributes 0.058
SMFM Consult Series #70: Management of short cervix in individuals without a history of spontaneous preterm birth
American Journal of Obstetrics and Gynecology202460 citations87 referencesContributes 0.047
Cervical elastography at 18 to 23 weeks to predict spontaneous preterm birth in individuals with a history of preterm birth
AJOG Global Reports20256 citations45 referencesContributes 0.043
Changes in use of 17-OHPC after the PROLONG trial: a physician survey
Journal of Perinatal Medicine20231 citations24 referencesContributes 0.029
The dosing regimen for 17-hydroxyprogesterone caproate was suboptimal: lessons for future pharmacotherapy for pregnant women
American Journal of Obstetrics and Gynecology20241 citations34 referencesContributes 0.020

Live enrichment

PubMed:37061078

Society For Maternal-Fetal Medicine

bronzeLicense: https://doi.org/10.15223/policy-004

publisherhttp://www.ajog.org/article/S0002937823002430/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0002937823002430?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0002937823002430?httpAccept=text/plain

MeSH Terms

HumansPremature BirthProgesteroneHydroxyprogesteronesPerinatologyPregnancyUnited States Food and Drug AdministrationInfant, NewbornUnited StatesFemale17 alpha-Hydroxyprogesterone Caproate

Keywords

Preterm BirthFood And Drug AdministrationCerclageVaginal Progesterone17-Alpha Hydroxyprogesterone Caproate